Pediatrix Medical announces Q3 adjusted EPS of 67 cents, surpassing consensus estimate of 47 cents.
Reports Q3 revenue $493M, consensus $476.44M. "Our operating results for the third quarter exceeded our expectations and were driven by a combination of reimbursement-related factors, including strong collection activity, higher patient acuity and slightly favorable payor mix, as well as operational consistency," said Mark Ordan, Chief Executive Officer of Pediatrix Medical Group. "We now expect our full year 2025 Adjusted EBITDA will likely range between $270 million and $290 million. We are of course pleased with our results, and the strength it provides to Pediatrix and our stakeholders, but know that they come at a time of change and uncertainty in the healthcare environment."
